PT

Palvella Therapeutics, Inc.

PVLA·NASDAQ

$115.42

+10%
HealthcareBiotechnology

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.37B
EPS-3.7100
P/E Ratio-31.11
Earnings Date08/13/2026

pvla

Common Stock

Last Annual Value

12.00K

3-Year CAGR

%

5-Year CAGR

-27%

10-Year CAGR

-14%

PT

Palvella Therapeutics, Inc. Competitors Analysis of Common Stock

PVLA · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
12.00K
N/A-30.1%N/A 
5.00K
7.7%4.6%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
30.00K
9.3%-82.6%N/A
9.00K
8.7%5.2%16.2%
SVRA logo
Savara Inc.
NASDAQ:SVRA
204.00K
13.4%12.0%44.9%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
87.00K
33.0%61.2%9.5%
10.00K
0.0%27.2%N/A
1.42B
1.7%2.0%5.1%
1.41B
2964.5%738.6%16.3%
PT

Palvella Therapeutics, Inc. Fair Value Envelope

PVLA · NASDAQ

Our analysis suggests that PVLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $115.42, this represents a potential HIDDEN relative to our calculated worth for Palvella Therapeutics, Inc..

Intrinsic Value
Current Price: $115.42